Literature DB >> 340643

A comparison of the analgesic effect of intramuscular nalbuphine and morphine in patients with postoperative pain.

W T Beaver, G A Feise.   

Abstract

In a double-study, using patients' subjective reports as indices of analgesia, the relative analgesic potency of intramuscular nalbuphine and morphine was determined in 56 postoperative patients. A total of 28 crossover comparisons (utilizing the twin passover, balanced four-point incomplete block design) were performed in two sequentially related experiments, each assay comparing 4 and 8 mg of morphine with either 3 and 6 or 6 and 12 mg of nalbuphine. When both intensity and duration of analgesia are considered (i.e., total analgesic effect), nalbuphine was 0.8 to 0.9 times as potent as morphine. In terms of peak analgesic effect, nalbuphine was 0.7 to 0.8 times as potent. Both the time-effect curves and the relative potency estimates suggest that nalbuphine has a slightly longer duration of action than morphine at doses that are equianalgesic in terms of peak effect. Side effects of the type usually noted after the administration of potent injectable analgesics to postoperative patients were observed after both morphine and nalbuphine. Although nalbuphine is a potent narcotic antagonist, no psychotomimetic reactions were observed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 340643

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

1.  The pharmacokinetics of oral and intravenous nalbuphine in healthy volunteers.

Authors:  A R Aitkenhead; E S Lin; K J Achola
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

Review 2.  [Nalbuphine in pediatric anesthesia].

Authors:  A-M Schultz-Machata; K Becke; M Weiss
Journal:  Anaesthesist       Date:  2014-02       Impact factor: 1.041

3.  Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis.

Authors:  Saadet Inan; Alvaro Torres-Huerta; Liselotte E Jensen; Nae J Dun; Alan Cowan
Journal:  Eur J Pharmacol       Date:  2019-09-27       Impact factor: 4.432

4.  Continuous infusion of propofol in dystrophia myotonica.

Authors:  D A White; D G Smyth
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

5.  The pharmacokinetics of intravenous, intramuscular, and subcutaneous nalbuphine in healthy subjects.

Authors:  M W Lo; F H Lee; W L Schary; C C Whitney
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Patient-controlled analgesia with nalbuphine, a new narcotic agonist-antagonist, for the treatment of postoperative pain.

Authors:  K A Lehmann; B Tenbuhs
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

7.  Pharmacokinetic Profiles of Nalbuphine after Intraperitoneal and Subcutaneous Administration to C57BL/6 Mice.

Authors:  Brenda L Kick; Pan Shu; Bo Wen; Duxin Sun; Douglas K Taylor
Journal:  J Am Assoc Lab Anim Sci       Date:  2017-09-01       Impact factor: 1.232

8.  Plasma histamine and hemodynamic responses following administration of nalbuphine and morphine.

Authors:  S M Muldoon; M A Donlon; R Todd; E A Helgeson; W Freas
Journal:  Agents Actions       Date:  1984-10

9.  Effect of nalbuphine on intrabiliary pressure in the early postoperative period.

Authors:  E Vatashsky; Y Haskel
Journal:  Can Anaesth Soc J       Date:  1986-07

10.  Experience with nalbuphine, a new opioid analgesic, in acute myocardial infarction.

Authors:  R A Greenbaum; G Kaye; P D Mason
Journal:  J R Soc Med       Date:  1987-07       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.